Korean J Med.
2013 Jul;85(1):67-72.
A Case of Hemolytic Uremic Syndrome after Transarterial Chemoembolization with Cisplatin
- Affiliations
-
- 1Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. kimkm70@amc.seoul.kr
Abstract
- Hemolytic uremic syndrome (HUS) is a rare disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. These characteristics are related to the formation of platelet-rich microthrombi in the microvasculature. HUS is associated with a variety of etiologies, including cisplatin. Previously reported HUS cases after cisplatin administration were almost always related to systemic combination chemotherapy that included cisplatin. Transarterial chemoembolization (TACE) is commonly used in treatment of hepatocellular carcinoma, and most centers in Korea use cisplatin. A 70-year-old female with hepatocellular carcinoma was treated with TACE including cisplatin and subsequently developed clinical and laboratory findings compatible with HUS.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A clinical aspect of the hemolytic uremic syndrome
- A Case of the Diarrhea-associated Hemolytic Uremic Syndrome Developing Simultaneously with an Acute Appendicitis
- A Case of Microangiopathic Hemolytic Anemia after Myxoma Excision and Mitral Valve Repair Presenting as Hemolytic Uremic Syndrome
- Delayed Hemolytic Uremic Syndrome Presenting as Diffuse Alveolar Hemorrhage
- Hemolytic-Uremic Syndrome
